These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23819360)

  • 21. Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy.
    Rosenkrantz AB; Ream JM; Nolan P; Rusinek H; Deng FM; Taneja SS
    AJR Am J Roentgenol; 2015 Dec; 205(6):1208-14. PubMed ID: 26587927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional vs. reduced field of view diffusion weighted imaging of the prostate: Comparison of image quality, correlation with histology, and inter-reader agreement.
    Warndahl BA; Borisch EA; Kawashima A; Riederer SJ; Froemming AT
    Magn Reson Imaging; 2018 Apr; 47():67-76. PubMed ID: 29103977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer.
    Rozenberg R; Thornhill RE; Flood TA; Hakim SW; Lim C; Schieda N
    AJR Am J Roentgenol; 2016 Apr; 206(4):775-82. PubMed ID: 27003049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging.
    Rosenkrantz AB; Kopec M; Kong X; Melamed J; Dakwar G; Babb JS; Taouli B
    J Magn Reson Imaging; 2010 Jun; 31(6):1387-94. PubMed ID: 20512891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The clinical value of 3 tesla diffusion-weighted magnetic resonance imaging in the diagnosis of prostate cancer].
    Shimamoto T; Ashida S; Yamasaki I; Kuno T; Fukuhara H; Fukata S; Satake H; Tamura K; Karashima T; Kamata M; Inoue K; Shuin T; Kariya S; Ogawa Y
    Hinyokika Kiyo; 2012 Mar; 58(3):143-8. PubMed ID: 22495042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantified analysis of histological components and architectural patterns of gleason grades in apparent diffusion coefficient restricted areas upon diffusion weighted MRI for peripheral or transition zone cancer locations.
    Helfrich O; Puech P; Betrouni N; Pinçon C; Ouzzane A; Rizk J; Marcq G; Randazzo M; Durand M; Lakroum S; Leroy X; Villers A
    J Magn Reson Imaging; 2017 Dec; 46(6):1786-1796. PubMed ID: 28383776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
    Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
    Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer: utility of diffusion-weighted imaging as a marker of side-specific risk of extracapsular extension.
    Rosenkrantz AB; Chandarana H; Gilet A; Deng FM; Babb JS; Melamed J; Taneja SS
    J Magn Reson Imaging; 2013 Aug; 38(2):312-9. PubMed ID: 23238968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical value of diffusion-weighted magnetic resonance imaging for localization of prostate cancer--comparison with the step sections of radical prostatectomy].
    Hatano K; Tsuda K; Kawamura N; Kakuta Y; Takada T; Adachi S; Hara T; Yamaguchi S
    Nihon Hinyokika Gakkai Zasshi; 2010 May; 101(4):603-8. PubMed ID: 20535988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens.
    Hoeks CM; Vos EK; Bomers JG; Barentsz JO; Hulsbergen-van de Kaa CA; Scheenen TW
    Invest Radiol; 2013 Oct; 48(10):693-701. PubMed ID: 23614975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
    Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
    Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging.
    Manenti G; Squillaci E; Di Roma M; Carlani M; Mancino S; Simonetti G
    Radiol Med; 2006 Dec; 111(8):1124-33. PubMed ID: 17171522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T2* relaxation time in the detection and assessment of aggressiveness of peripheral zone cancer in comparison with diffusion-weighted imaging.
    Wu LM; Zhou B; Lu Q; Suo ST; Liu Q; Hu J; Haccke EM; Chen XX; Xu JR
    Clin Radiol; 2016 Apr; 71(4):356-62. PubMed ID: 26823021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy.
    Verma S; Rajesh A; Morales H; Lemen L; Bills G; Delworth M; Gaitonde K; Ying J; Samartunga R; Lamba M
    AJR Am J Roentgenol; 2011 Feb; 196(2):374-81. PubMed ID: 21257890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apparent diffusion coefficient value is a strong predictor of unsuspected aggressiveness of prostate cancer before radical prostatectomy.
    Renard Penna R; Cancel-Tassin G; Comperat E; Mozer P; Léon P; Varinot J; Roupret M; Bitker MO; Lucidarme O; Cussenot O
    World J Urol; 2016 Oct; 34(10):1389-95. PubMed ID: 26902878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer.
    Rosenkrantz AB; Sigmund EE; Johnson G; Babb JS; Mussi TC; Melamed J; Taneja SS; Lee VS; Jensen JH
    Radiology; 2012 Jul; 264(1):126-35. PubMed ID: 22550312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results.
    Kim CK; Park BK; Han JJ; Kang TW; Lee HM
    J Comput Assist Tomogr; 2007; 31(3):449-54. PubMed ID: 17538295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of prostate cancer aggressiveness using apparent diffusion coefficient values: impact of patient race and age.
    Tamada T; Prabhu V; Li J; Babb JS; Taneja SS; Rosenkrantz AB
    Abdom Radiol (NY); 2017 Jun; 42(6):1744-1751. PubMed ID: 28161826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Prostate Imaging Reporting and Data System versions 1 and 2 for the Detection of Peripheral Zone Gleason Score 3 + 4 = 7 Cancers.
    Krishna S; McInnes M; Lim C; Lim R; Hakim SW; Flood TA; Schieda N
    AJR Am J Roentgenol; 2017 Dec; 209(6):W365-W373. PubMed ID: 28981356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical applications of diffusion-weighted-MRI in prostate cancer.
    Wibulpolprasert P; Phongkitkarun S; Chalermsanyakorn P
    J Med Assoc Thai; 2013 Aug; 96(8):967-75. PubMed ID: 23991605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.